SCHEMBL2292350

SCHEMBL2292350

OCc1ccc(-c2cn(Cc3ccccc3)c3ccccc23)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.57
ALDH1A1 P00352 4/20 0.57
LMNA P02545 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
HIF1A Q16665 2/20 0.57
EPAS1 Q99814 2/20 0.57
KDM4E B2RXH2 2/20 0.57
MAPT P10636 2/20 0.57
RAB9A P51151 2/20 0.57
NPC1 O15118 1/20 0.57
GMNN O75496 1/20 0.57
TP53 P04637 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
NFKB1 P19838 1/20 0.57
MAPK1 P28482 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5354003 0.78 SIRT2 (0.51) ALDH1A1LMNASMN1; SMN2KDM4EMAPT
SCHEMBL4754296 0.77 SIRT2 (0.61) ALDH1A1LMNASMN1; SMN2SIRT2POLB
SCHEMBL5355132 0.76 F2RL3 (0.62) ALDH1A1LMNASMN1; SMN2MAPK1SIRT2
SCHEMBL5359539 0.75 MAPT (0.58) ALDH1A1LMNASMN1; SMN2KDM4EMAPT
SCHEMBL5358132 0.74 DYRK1A (0.47) PDE5AALDH1A1LMNASMN1; SMN2HIF1A
SCHEMBL5354579 0.74 SIRT2 (0.49) ALDH1A1LMNASMN1; SMN2KDM4EMAPT
SCHEMBL7113697 0.74 POLB (0.74) ALDH1A1LMNASMN1; SMN2MAPK1POLB
SCHEMBL5359254 0.73 HTR6 (0.61) LMNASMN1; SMN2CYP3A4CYP2D6CA12
SCHEMBL187837 0.73 PDE5A (1.00) PDE5AALDH1A1LMNASMN1; SMN2HIF1A
SCHEMBL29352550 0.73 PDE5A (1.00) PDE5AALDH1A1LMNASMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106233141-A Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell 罗伯特·I·汉金 2016-12-14 CN claimed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
CN-109689649-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2022-07-19 CN disclosed
CN-109689664-B Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors 百时美施贵宝公司 2022-04-15 CN disclosed
CN-109689642-B Monocyclic heteroaryl substituted compounds 百时美施贵宝公司 2022-04-12 CN disclosed
CN-106470995-A Imidazo [1,2-a ] pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases 拜耳医药股份有限公司 2017-03-01 CN disclosed
CN-104159899-B Substituted triazine derivatives and their use as activators of soluble guanylate cyclase 拜耳知识产权有限责任公司 2017-02-22 CN disclosed
CN-106459047-A Imidazo [1,2-a ] pyridines as stimulators of soluble guanylate cyclase for the treatment of cardiovascular diseases 拜耳医药股份有限公司 2017-02-22 CN disclosed
CN-106459037-A Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases 拜耳医药股份有限公司 2017-02-22 CN disclosed
CN-106459090-A 3-(pyrimidine-2-yl)imidazo[1,2-A]pyridines 拜耳制药股份公司 2017-02-22 CN disclosed
US-7989650-B2 Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs HEMOCORM LIMITED (GB) 2011-08-02 US disclosed
EP-2135605-A2 Therapeutic delivery of carbon monoxide Hemocorm Limited (GB) 2009-12-23 EP disclosed
US-7176230-B2 Synthesis of indole analogs of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl) indazole (YC-1) as anti-platelet agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2007-02-13 US disclosed
US-20060127501-A1 Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs HEMOCORM LIMITED (GB) 2006-06-15 US disclosed
US-20060115542-A1 THERAPEUTIC DELIVERY OF CARBON MONOXIDE HEMOCORM LIMITED (GB) 2006-06-01 US disclosed
US-20060106041-A1 Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2006-05-18 US disclosed
US-7045140-B2 Therapeutic delivery of carbon monoxide HEMOCORM LIMITED (GB) 2006-05-16 US disclosed
EP-1399147-A2 THERAPEUTIC DELIVERY OF CARBON MONOXIDE Northwick Park Institute For Medical Research (GB) 2004-03-24 EP disclosed
US-20030064114-A1 Therapeutic delivery of carbon monoxide HEMOCORM LIMITED (GB) 2003-04-03 US disclosed
WO-2002092075-A2 THERAPEUTIC DELIVERY OF CARBON MONOXIDE NORTHWICK PARK INSTITUTE FOR MEDICAL RESEARCH (GB) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106041-A1 Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents PFKP, HMOX1, TPH1 PDE5A 736/4885ALDH1A1 1624/4885LMNA 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.